{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:25:59Z","timestamp":1791951959016,"version":"4.3.4"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jchromb.2021.122643","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T09:41:39Z","timestamp":1615110099000},"page":"122643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Determination of finerenone \u2013 a novel, selective, nonsteroidal mineralocorticoid receptor antagonist \u2013 in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study in venous and capillary human plasma"],"prefix":"10.1016","volume":"1172","author":[{"given":"Gabriele","family":"Rohde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Loewen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4645-5428","authenticated-orcid":false,"given":"Roland","family":"Heinig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2021.122643_b0005","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.jchromb.2021.122643_b0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: Comparison at bench and bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.jchromb.2021.122643_b0015","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94\u20138862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"Barfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jchromb.2021.122643_b0020","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Mineralocorticoid receptor antagonist tolerability study-diabetic nephropathy study group, effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jchromb.2021.122643_b0025","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jchromb.2021.122643_b0030","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jchromb.2021.122643_b0035","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/fcp.12170","article-title":"Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies","volume":"30","author":"Lentini","year":"2016","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2021.122643_b0040","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s13318-018-0483-9","article-title":"Pharmacokinetics of the novel, selective, non-steroidal mineralocorticoid receptor antagonist finerenone in healthy volunteers: results from an absolute bioavailability study and drug\u2013drug interaction studies in vitro and in vivo","volume":"43","author":"Heinig","year":"2018","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jchromb.2021.122643_b0045","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1124\/dmd.118.083337","article-title":"Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivo and in vitro","volume":"46","author":"Gerisch","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jchromb.2021.122643_b0050","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/cpdd.263","article-title":"Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94\u20138862) in individuals with renal impairment","volume":"5","author":"Heinig","year":"2016","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.jchromb.2021.122643_b0055","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40262-019-00820-x","article-title":"Population pharmacokinetic and exposure-response analysis of finerenone: insights based on phase IIb data and simulations to support dose selection for pivotal trials in type 2 diabetes with chronic kidney disease","volume":"59","author":"Snelder","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jchromb.2021.122643_b0060","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), Guidance for industry: bioanalytical method validation, https:\/\/collections.nlm.nih.gov\/catalog\/nlm:nlmuid-101734209-pdf, 2018 (accessed 29 Jan 2021)."},{"key":"10.1016\/j.jchromb.2021.122643_b0065","unstructured":"European Medicines Agency, Guideline on bioanalytical method validation, https:\/\/www.ema.europa.eu\/en\/bioanalytical-method-validation, 2011 (accessed 29 Jan 2021)."},{"key":"10.1016\/j.jchromb.2021.122643_b0070","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s13318-020-00610-y","article-title":"Results from drug-drug interaction studies in vitro and in vivo investigating the effect of finerenone on the pharmacokinetics of comedications","volume":"45","author":"Heinig","year":"2020","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jchromb.2021.122643_b0075","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2125.2010.03668.x","article-title":"Can finger-prick sampling replace venous sampling to determine the pharmacokinetic profile of oral paracetamol?","volume":"70","author":"Mohammed","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2021.122643_b0080","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/cpdd.290","article-title":"Comparison of capillary and venous drug concentrations after administration of a single dose of risperidone, paliperidone, quetiapine, olanzapine, or aripiprazole","volume":"5","author":"Remmerie","year":"2016","journal-title":"Clin. Pharmacol. Drug Dev."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023221001239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023221001239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:04:10Z","timestamp":1761606250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023221001239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":16,"alternative-id":["S1570023221001239"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2021.122643","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of finerenone \u2013 a novel, selective, nonsteroidal mineralocorticoid receptor antagonist \u2013 in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study in venous and capillary human plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2021.122643","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122643"}}